Karen Woodson

Karen Woodson

Auto-generated profile, based on publicly available information

Karen Woodson

Cancer Prevention Studies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2006 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
JHJeffrey A. Hanson
Jeffrey A. Hanson
JGJohn W. Gillespie
John W. Gillespie
AGAmelia Grover
Amelia Grover
MTMichael A. Tangrea
Michael A. Tangrea
RCRodrigo F. Chuaqui
Rodrigo F. Chuaqui
KWKaren G. Woodson
Karen G. Woodson
Background: Gene expression can be silenced through the methylation of specific sites in the promoter region. This mechanism of gene silencing has an important role in the carcinogenesis of prostate and other cancers. Although tumor-associated stromal cells also exhibit changes in gene expression, promoter methylation has not been described in these cells. Methods: Tumor epithelia, tumor-associated stroma and normal epithelia, and stroma adjacent to tumor tissues were isolated from whole-mount prostatectomy specimens (two per patient) of patients ( n = 5) with localized prostate cancer and from normal epithelia and stroma from benign prostate hyperplasia specimens (two per patient) from men ( n = 5) without prostate cancer by using laser capture microdissection or expression microdissection. The methylation status of three genes important in prostate carcinogenesis, GSTP1, RAR β2, and CD44, were evaluated using quantitative methylation-sensitive polymerase chain reaction. Results: GSTP1 and RARβ2 were methylated in the tumor epithelium of all five prostate cancer patients and in the tumor-associated stroma in four of the five patients. CD44 was methylated in the tumor epithelium from four of the five patients but not in the tumor stroma. GSTP1 and RARβ2 were methylated in normal epithelium of two and four patients, respectively, and in normal stroma of one and two patients, respectively, that were isolated from regions adjacent to the tumors and may have resulted from a tumor-field effect; CD44 methylation was not observed in normal epithelium or stroma. In contrast, normal epithelia and stroma from benign prostate hyperplasia specimens showed no promoter methylation in GSTP1, RARβ2, or CD44. Conclusions: The observation of promoter methylation in the non-neoplastic cells of the prostate tumor microenvironment may advance our understanding of prostate cancer development and progression and lead to new diagnostic and prognostic markers and therapeutic targets.

4 April 2003 in The Prostate
Verified
Journal Article
Closed access
PDF file
KWKaren Woodson
Karen Woodson
RHRichard Hayes
Richard Hayes
LWLouise Wideroff
Louise Wideroff
LVLiza Villaruz
Liza Villaruz
JTJoseph Tangrea
Joseph Tangrea

1 August 2003 in Cancer Causes & Control
Verified
Journal Article
Closed access
PDF file
KWKaren Woodson
Karen Woodson
JTJoseph A. Tangrea
Joseph A. Tangrea
TLTeresa A. Lehman
Teresa A. Lehman
RMRamakrishna Modali
Ramakrishna Modali
KTKristin M. Taylor
Kristin M. Taylor
DADemetrius Albanes
Demetrius Albanes

2 March 2004 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
KWKaren Woodson
Karen Woodson
AFAndrew Flood
Andrew Flood
LGLisa Green
Lisa Green
JTJoseph A. Tangrea
Joseph A. Tangrea
JHJeffrey Hanson
Jeffrey Hanson
PSPhillip Schoenfeld
Phillip Schoenfeld
Loss of imprinting (LOI) of insulin-like growth factor-II (IGF-II) may be an inherited epigenetic trait that is polymorphic in the population, and its presence may predispose an individual to the development of colorectal cancer. We evaluated the association between LOI of IGF-II in normal colonic mucosal samples and adenomas in women participating in a colonoscopy screening study. Among 40 participants, 11 (27.5%) had LOI of IGF-II in their normal colonic mucosal tissue. After adjusting for body mass index and family history of colorectal cancer, LOI status was associated with a fivefold increased risk of adenoma formation (odds ratio = 5.2, 95% confidence interval = 1.0 to 26.7). On average, IGF-II expression was more than threefold higher among women with LOI of IGF-II than among women with normal imprinting status. Our findings support the hypothesis that LOI of IGF-II is an epigenetic trait polymorphic in the population and suggest that LOI of IGF-II may play a role in colorectal cancer. These findings are intriguing and need to be confirmed in larger studies.

1 March 2004 in Cancer Letters
Verified
Journal Article
Closed access
KWKaren Woodson
Karen Woodson
JHJeffrey Hanson
Jeffrey Hanson
JTJoseph Tangrea
Joseph Tangrea

23 October 2006 in Epigenetics
Verified
Journal Article
Closed access
KWKaren Woodson
Karen Woodson
KOKeith J O’rEilly
Keith J O’rEilly
DWDavid E Ward
David E Ward
JWJack Walter
Jack Walter
JHJeffery Hanson
Jeffery Hanson
JTJoseph A Tangrea
Joseph A Tangrea
Up to 30% of men with clinically localized disease who receive radical prostatectomy develop a biochemical recurrence. Gene methylation in tumor tissue may distinguish men with aggressive cancer. This study evaluated methylation of GSTP1, RARβ2, CD44 and PTGS2 with biochemical recurrence among 60 patients who underwent radical prostatectomy using logistic regression and Kaplan Meier time to event analysis. Methylation of GSTP1 and RARβ2 was not associated with recurrence, however, CD44 and PTGS2 methylation were significant predictors. In multivariate models adjusting for Gleason grade, methylation profile of CD44 and PTGS2 combined was an independent predictor of biochemical recurrence (associated with 9-fold increased risk). In addition, Kaplan Meier analysis showed CD44 and PTGS2 methylation was associated with shorter time to recurrence. CD44 and PTGS2 methylation may predict biochemical recurrence in prostate cancer patients undergoing radical prostatectomy and if validated in larger studies, may ide...